Novacyt: on these numbers, the cheapest stock on the market
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?
Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.REGISTER FREE
More on Novacyt SA
Shares in a company we have covered since IPO soared on strong results and a very…
Jeremy Clarkson has a new show on Amazon Prime about his farm. The series reveals the highs…